BioNTech (NASDAQ:BNTX) and OncoC4 reported updated Phase 3 PRESERVE-003 data showing median overall survival of 18.5 months with gotistobart versus 10.0 months with docetaxel in previously treated squamous NSCLC.
BioNTech (NASDAQ:BNTX), the biotechnology firm that rose to global prominence with its COVID-19 vaccine, reported full-year 2025 revenues of €2.87 billion on Tuesday.
BioNTech (NASDAQ:BNTX) announced today its comprehensive participation in the European Lung Cancer Congress (ELCC) 2026, where the company will present updated data across its diversified lung cancer portfolio.
